Trials / Completed
CompletedNCT04345887
Spironolactone in Covid-19 Induced ARDS
The Effect of Spironolactone on Oxygenation in Covid-19 ARDS Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (actual)
- Sponsor
- Istanbul University - Cerrahpasa · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study intended to evaluate the effects of commonly used diuretic, spironolactone, on oxygenation in covid-19 ARDS patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Spironolactone 100mg | 2x100 mg spironolactone for 5 consecutive days |
| DRUG | Placebo oral tablet | 2 x1 placebo tablet |
Timeline
- Start date
- 2020-05-05
- Primary completion
- 2020-06-15
- Completion
- 2020-07-05
- First posted
- 2020-04-15
- Last updated
- 2021-10-28
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT04345887. Inclusion in this directory is not an endorsement.